Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.
BACKGROUND
Plasma cells constitute the majority of tumor cells in multiple myeloma (MM) but lack the potential for sustained clonogenic growth. In contrast, clonotypic B cells can engraft and recapitulate disease in immunodeficient mice suggesting they serve as the MM cancer stem cell (CSC). These tumor initiating B cells also share functional features with normal stem cells such as drug resistance and self-renewal potential. Therefore, the cellular processes that regulate normal stem cells may serve as therapeutic targets in MM. Telomerase activity is required for the maintenance of normal adult stem cells, and we examined the activity of the telomerase inhibitor imetelstat against MM CSC. Moreover, we carried out both long and short-term inhibition studies to examine telomere length-dependent and independent activities.


RESULTS
Human MM CSC were isolated from cell lines and primary clinical specimens and treated with imetelstat, a specific inhibitor of the reverse transcriptase activity of telomerase. Two weeks of exposure to imetelstat resulted in a significant reduction in telomere length and the inhibition of clonogenic MM growth both in vitro and in vivo. In addition to these relatively long-term effects, 72 hours of imetelstat treatment inhibited clonogenic growth that was associated with MM CSC differentiation based on expression of the plasma cell antigen CD138 and the stem cell marker aldehyde dehydrogenase. Short-term treatment of MM CSC also decreased the expression of genes typically expressed by stem cells (OCT3/4, SOX2, NANOG, and BMI1) as revealed by quantitative real-time PCR.


CONCLUSIONS
Telomerase activity regulates the clonogenic growth of MM CSC. Moreover, reductions in MM growth following both long and short-term telomerase inhibition suggest that it impacts CSC through telomere length-dependent and independent mechanisms.
Brennan
Sarah K
SK
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Wang
Qiuju
Q
Tressler
Robert
R
Harley
Calvin
C
Go
Ning
N
Bassett
Ekaterina
E
Huff
Carol Ann
CA
Jones
Richard J
RJ
Matsui
William
W
D000818:Animals; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002999:Clone Cells; D015536:Down-Regulation; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D009101:Multiple Myeloma / Q000201:enzymology* / Q000378:metabolism / Q000503:physiopathology*; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000201:enzymology / Q000378:metabolism; D019098:Telomerase / Q000378:metabolism*; D016615:Telomere / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D019098:Telomerase
Clin Cancer Res. 2010 Jan 1;16(1):154-63
20048334
Cancer. 2002 Apr 15;94(8):2232-8
12001122
J Cell Physiol. 1999 Nov;181(2):251-7
10497304
Cell. 1997 Oct 3;91(1):25-34
9335332
Science. 1997 Aug 15;277(5328):955-9
9252327
Nature. 2009 Jan 15;457(7227):277-80
19098894
PLoS Genet. 2008 Jan;4(1):e10
18208333
J Clin Oncol. 2005 May 20;23(15):3412-20
15809451
Cancer Res. 1998 Dec 1;58(23):5406-10
9850072
Cancer Genet Cytogenet. 1997 Jan;93(1):56-62
9062581
Nat Genet. 2003 Feb;33(2):203-7
12539050
J Urol. 2001 Aug;166(2):694-8
11458119
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6476-81
8692840
Genes Dev. 2008 Mar 1;22(5):654-67
18283121
J Immunol. 1995 Oct 15;155(8):3711-5
7561072
Nat Immunol. 2005 Mar;6(3):314-22
15665828
Science. 1994 Dec 23;266(5193):2011-5
7605428
Science. 2009 May 8;324(5928):797-801
19325077
Cancer Res. 2008 Jan 1;68(1):190-7
18172311
Nature. 2009 Jul 2;460(7251):66-72
19571879
Cell. 1985 Dec;43(2 Pt 1):405-13
3907856
Dev Genet. 1996;18(2):173-9
8934879
Clin Cancer Res. 2004 Jan 15;10(2):770-6
14760100
Eur J Cancer. 1997 Apr;33(5):787-91
9282118
Leukemia. 2008 Jul;22(7):1410-8
18449204
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15960-4
16247010
Methods Mol Biol. 2007;405:9-22
18369813
Cancer Res. 2003 Oct 1;63(19):6187-94
14559802
Blood. 2003 Jun 15;101(12):4982-9
12609839
Int J Cancer. 2009 Jul 1;125(1):235-43
19358275
J Natl Cancer Inst. 2010 Apr 21;102(8):520-1
20388877
Genes Cells. 1999 Oct;4(10):563-72
10583505
Blood. 2004 Mar 15;103(6):2332-6
14630803
Clin Cancer Res. 2006 May 15;12(10):3184-92
16707619
Blood. 2004 Jan 1;103(1):258-66
12969977
Blood. 1998 May 1;91(9):3255-62
9558381
J Exp Med. 2007 Apr 16;204(4):831-40
17389240
Nature. 2003 May 15;423(6937):255-60
12714970
Blood. 2005 Jun 1;105(11):4163-9
15687234
Leukemia. 2009 Dec;23(12):2222-32
19741729
Blood. 2003 Jul 15;102(2):517-20
12663456
Mol Cancer Ther. 2003 Sep;2(9):825-33
14555701
N Engl J Med. 2005 Apr 7;352(14):1413-24
15814878
Nature. 2005 Aug 18;436(7053):1048-52
16107853
Cancer Cell. 2007 Dec;12(6):528-41
18068630
Nature. 2001 Nov 1;414(6859):105-11
11689955
Genes Dev. 1999 Sep 15;13(18):2388-99
10500096
Mol Cell Biol. 1996 Jan;16(1):53-65
8524329
Lancet. 2002 Jun 22;359(9324):2168-70
12090986
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11306-11
16847266
Neuro Oncol. 2008 Apr;10(2):112-20
18287341
J Cell Physiol. 1997 Nov;173(2):266-70
9365534
Cancer Res. 2005 Sep 1;65(17):7866-73
16140956
Oncogene. 2002 Jan 21;21(4):638-42
11850790
Cell. 2005 Dec 16;123(6):1121-31
16360040
Blood. 2002 Apr 15;99(8):2767-75
11929765
Cancer Res. 2000 Feb 1;60(3):610-7
10676644
Science. 1995 Sep 1;269(5228):1236-41
7544491
Cell. 2003 Jul 25;114(2):241-53
12887925
Nature. 1990 Mar 8;344(6262):126-32
1689810
J Biol Chem. 2005 Jun 24;280(25):23709-17
15831499
Cancer Res. 2007 Feb 1;67(3):1121-9
17283146
Science. 2007 Dec 21;318(5858):1917-20
18029452